Member Info for The_Paladin

An excellent and concise explanation Bryosa, and one with which I concur. Have you considered applying for the position of Synairgen's Senior Medical Writer? Your explanation fulfils the post's criteria. ATB.

"We are looking for writer with a passion for scientific storytelling to write medical/scientific content that will engage and educate diverse audiences. The role will involve developing and writing engaging, accurate and fully referenced scientific, clinical and medical copy for a wide variety of audiences."

Thank you Docdaneeka for adding some realism, and factual perspective to my very own Synairgen arrow.

I appreciate that I am not comparing like with like in that Evusheld protects the patient against the virus onset, whereas Synairgen's SNG001 could potentially provide an effective early stage treatment for an immunosuppressed patient, who had caught Covid. It could prove to be paricularly beneficial for the immunosuppressed bearing in mind its safety record over multiple trials, and its added value in potentially suppressing the onset and development of Long Covid symptoms?

It was just an idea that occurred to me when reading the BBC article earlier today. Should it get as far as a specialist at Synairgen,they may well dismisss it without further thought?

At this point in time with eight months in the doldrums despite multiple encouraging signs emerging from Synairgen, it is necessary for the company to participate in another SNG001 P3 trial asap. I trust that the company is exploring every available trial opportunity, and my idea (ill thought through or otherwise) was one that I chose to check out with them. Most probably, it won't merit a reply?

ATB and GLA.

I have been a bullish "bull to a gate" this morning and have written to Brooke Clarke regarding the potential of Synairgen as a treatment for immunosuppressed patients?

"Good morning Mrs Clarke,

I read the attached article earlier and wondered whether Synairgen are pursuing a trial with a view of treating immunosuppressed patients following approval?
Surely, Synairgen could potentially offer a better treatment to this category of patient than AZ’s Evushield? Our product (I am a significant investor), with its safety data and potential for preventing the onset of Long Covid symptoms should have a chance of qualifying for a trial as a drug for the treatment of the immunosuppressed with Covid symptoms? In addition, with P2 data, P3 Sprinter deep dive and Long Covid data, and the recent data from the Activ-2 trial, surely promising early results from a P3 trial would put us on track to submit an application for an EUA to treat patients in the immunosuppressed category?

https://www.bbc.co.uk/news/health-63254155

I appreciate that Synairgen has a busy week ahead with Dr. Monk’s PASC data presentation on Oct 21, but would be interested to learn whether the aforementioned qualifies as one of Synairgen’s “arrows” in flight towards a potential target?"

I will report back should I receive a reply.

What about Synairgen as an effective treatment to prevent the spread of Covid in immunosuppressed patients, and with the additional benefit of significantly reducing the possibility of Long Covid subsequently? Surely a better option for severely compromised individuals than AZ's offering?
Note the last line: "Ministers say they are urgently looking into setting up clinical trials, but it's unlikely that any results will be available until late spring at the earliest."

From the BBC website.
"Time is running out for hundreds of thousands of vulnerable people who are facing another winter shielding from Covid, campaigners have said.They are calling on the government to buy a drug called Evusheld to provide some protection against the virus.The government says it is not clear how long that protection will last when up against the Omicron variant.
But patients, charities and health experts argue the protection offered is better than nothing.

There are around 500,000 people in the UK alone with suppressed immune systems.

Evusheld, manufactured by AstraZeneca, was approved by the UK medicines regulator in March and is already available in more than 30 other countries. But in August the government said it wouldn't be buying any doses until it had more data.
In particular, there are some concerns over how long protection may last against the Omicron variant of Covid.
Ministers say they are urgently looking into setting up clinical trials, but it's unlikely that any results will be available until late spring at the earliest."

It is evident from the last sentence that Dr. Monk is open to engaging interested parties in conversation. A similar approach was used when he presented at a recent conference in Cambridge.

https://twitter.com/synairgenplc/status/1580891989129670657?s=46&t=KzCosdNfwrdAKYpMS3vfQg

To change the subject, the number of individuals infected with Covid is rising sharply, and with it the number of hospitalisations. It is premature to predict the number of deaths under the current variant of concern. I received my latest vaccination of Comirnaty Original/Omicron BA.1 yesterday. I was surprised to find that the queue was mostly comprised of young people in their mid teens to early twenties.
The latest news reports, such as the one below are worrying. It was irresponsible of President Biden and Dr Tedros to announce tecently that the pandemic was over. We all hope that there will be no major virus escalation this coming Winter, but it shouldn’t be dismissed until there is considerably more data available than at present.

“Covid-19 patient levels in England are at their highest since the end of July with health experts warning of “sustained increases” in infections and admissions.
The number of deaths where coronavirus is mentioned on a person's death certificate are also starting to rise.
The figures come as more than half of people aged 75 and over in England have now received an autumn booster dose of Covid-19 vaccine, with bookings opening on Friday for everyone aged 50 and above.
A total of 10,608 patients testing positive for coronavirus were in hospital as of 8am on October 12, according to NHS England. This is up 10 per cent from 9,631 a week earlier and is the highest figure since July 29.
Patient numbers topped 14,000 in mid-July at the peak of the wave of infections caused by the Omicron BA.4 and BA.5 subvariants of the virus, then fell steadily until mid-September.
Numbers have risen in recent weeks, signalling Covid-19 is once again becoming more prevalent.
Dr Mary Ramsay, director of public health programmes at the UK Health Security Agency (UKHSA), said: “We're seeing sustained increases in Covid-19 cases and hospitalisation rates, so we continue to urge those eligible for vaccinations to come forward, whether that's a first dose or a booster.
“There are early indications that deaths with Covid-19 have also started to rise. Whilst this is concerning, it is too early to say whether these are deaths due to Covid-19 and it is reassuring that at this stage there is no overall excess mortality.”

Thank you Ghia.

Your scenario was the only one that I could envisage. I immediately dismissed it on the grounds that it might be illegal? Would a BP company be allowed to enact differentiated “free market” style transactions? It is an interesting scenario, which I shall further investigate when I have the time.

GLA.

TommyD__19,
Thank you for sharing an accessible and informative paper.

With regard to a future SNG001 trial, I am considering the role our treatment would play in alleviating PASC symptoms? My understanding is that our product is an early stage treatment targeting patients with severe breathing problems.
In “putting out the fire”, as RM once remarked, the virus spread to other organs and tissues would be considerably attenuated resulting in the removal of PASC symptoms?
Could SNG001 also be used to alleviate the symptoms of PASC ? In other words would an interferon-based treatment be effective fir late stage Long Covid symptoms ? Should this be the case, would the inhalation of interferon provide the best route in channeling the drug to the source of the symptoms?

I have stated my questions in layman’s terms. The fact that a respected specialist’s opinion, based on Synairgen’s qualitative data, suggests that our treatment merits further investigation is encouraging. Inclusion on a PASC trial would surely put SNGO01 back in business, and with it our long suffering investments?

GLA.

Ghia,

I would also be interested to hear your opinion regarding TFG Asset Management’s strategy. Is there a scenario where they could turn a profit, and at the same time leaving retail investors, who are invested at the same average share price as TFG, at a loss? Surely they would have difficulty in achieving this while declaring all their transactions ?

Your comment has piqued my interest and I would welcome further clarification.

ATB and GLA.

The recent paper from the JEM is relevant in that it shows the correlation between age, interferon production/immune response, and the severity of Covid-19 symptoms in a mice study. It may have relevance in the trial design for interferon-based treatments.

“Severity of COVID-19 shows an extraordinary correlation with increasing age. We generated a mouse model for severe COVID-19 and show that the age-dependent disease severity is caused by the disruption of a timely and well-coordinated innate and adaptive immune response due to impaired interferon (IFN) immunity.”

https://rupress.org/jem/article/219/12/e20220621/213485/Impaired-immune-response-drives-age-dependent

Apologies if already posted.

My previous comment is out of date. The trading volume has increased during the last 1/2hr. Another shopping expedition?

Less than 0.076% of Synairgen’s shares have been traded today. Yet the share price displayed is 10% down on yesterday’s closing price?

I could sell all my shares in one transaction at a higher price. Similarly, if I were aspiring to add, it would be at a considerably higher price than 17.01p?

Why does the London Stock Exchange consistently fly these false flags? They rarely achieve congruence with reality?

As a Synairgen investor, I am focused on the company achieving a trial invitation. Strive or a JV with a BP company are at the forefront of my mind?
I am assuming a Covid-19 trial, although it may be something different ? Some questions occurred to me about this:
a) The recruitment of a sufficient number of severely unwell patients to provide statistically significant data to verify SNG001’s efficacy? This has been our major issue in the past. We need to demonstrate the latter when patients who receive SNG001 treatment, and placebo patients, are both being treated with an appropriate SOC at the same time. How can Synairgen ensure that the trial is a fair test if it is conducted in multiple countries, with different SOC, and with some patients being allowed to leave the trial before all doses are administered? These factors may well have contributed to our lack of success in February?
b) Wearing my investor hat, will there be a significant upgrade to the share price should we achieve a further major trial? The answer to that question is surely yes? Following the start of the Sprinter trial, the share price met several bumps along the road. With the first vaccine approval, the share price declined to 80p or thereabouts. There was a short P&D raid when The Lancet P2 peer review was published, but the share price declined again shortly afterwards. There was a similar decline following the P2 Home Webinar the following February . The share price recovered well from that point by the end of 2021.

Is it therefore reasonable to assume that a place on a major trial, and with it a route to commercialisation, might well give us a x4 uplift back to the 80-90p range? It is logical to think that this could happen?

With my realist hat still in place, I fully appreciate that we will remain where we are unless an incoming trial emerges, or BP expressed a wish to acquire the company? Both alternatives would give us a good reason to be cheerful in my opinion.

Worth repeating Ben Fountain’s clear explanation on LinkedIn, two months ago, of what this investment is all about. Anything as complex as this takes time to establish. Trade it if you like. In my portfolio it remains a long term investment.

“Fintech pioneers Supply@ME Capital plc and VeChain Foundation, in partnership, are very soon going to announce the worlds first TrueSale Inventory Monetisation transaction. This will completely change the way businesses, especially SME's are financed, forever.

By securing a "Loan" against an agreed market value of your company warehouse stock in the form of true sale, using blockchain technology and smart contracts, you can release money / cash tied up in your business off book, with no negative cash balance showing on the balance sheet.

When the time comes to sell your warehoused goods / inventory to your consumer / customers, you simply buy / purchase back some or all of your goods from Supply@Me for the pre agreed price (including your loan fee) to then re-sell them on to your customer for a profit. The blockchain is then adjusted to reflect the new total and can be monitored from start to finish by all authorised parties using their realtime platform.

Add in the fact that Supply@Me also offer endtoend financing via their subsidiary TradeFlow Capital Management (TFC) for InTransit (being transported) goods, you can see they really do have the whole package taken care of for any client contemplating taking advantage of this service. DP World DPWorld liked the business model so much, they now offer the service themselves to their clients through a WhiteLabel offering in partnership with Supply@Me and Tradeflow.

SYME's business models are Sharia law compliant so can operate in UAE / MiddleEast countries, working with their funding partner Intesa Sanpaolo Intessa Sanpoalo Bank. The platform is also being rolled out across USA / Americas with assistance from Tony Brown, a world leader in Supply Chain Finance. Europe, Oceanic and Asian markets are able to take advantage also.

This business model also holds a massive opportunity for companies to keep on hand additional stock at minimal extra cost to themselves, which in turn help alleviate the SupplyChain crisis we are seeing all over the world at present. Not only this, but it helps create a fairer market with up to date tracking of commodity prices / values which are used for all financing packages creating a level playing field for all.”

Thanks gunto2022.

That comment has cheered me up. I hope that you are right. ATB

Agreed. I ran a ruler over the costs of ICU hospitalisation and treatment, as well as less intensive alternatives, at the outset of my Synairgen investment.

Although the situation has moved forward since then, a course of treatment with Synairgen is well -justified when compared with the costs of the alternatives available for severely unwell patients.

The Synairgen team will have these cost comparisons at their disposal, and that aspect should not pose a problem.

Always happy to read measured arguments from contributors of quality like Tornadotony. His contributions have weighted in heavily on this forum’s ongoing deliberations over the last two years, and added to the conversation. I am also happy to read that he has recovered his losses.

What I find abhorrent is the individuals who trash my Synairgen investment with their malicious comments about the company, and their employees. IMHO it is best to filter these individuals, and not waste any time in responding to their pointless nonsense.

GLA.

Brooke Clarke is keeping the news flowing. Yesterday, she reissued the following on LinkedIn with added detail. There are plenty of recent updates clustered together for anyone requiring information about the company.

“BTS for British Thoracic Society - we joined the Synairgen Research Ltd in Southampton for our upcoming programme, 'Lungs Matter' to discuss the annual impact of seasonary respiratory infections, and what it's like for patients and clinicians to be in respiratory distress.
Watch out for the full programme, launching at the BTS Annual Conference in November.

ITN Business team: Shannon Fairchild, Ahu Michaelides, Donna Bernard, Adam Ford #LungsMatter #ITNBusiness #BTS”

Hold4results. My Statistics text might prove to be too simplistic for you? It is one of the “Teach yourself” books (a cheap kindle purchase) pitched at GCSE standard. This is fine for me as I hadn’t studied the subject beforehand. ATB.

I am also checking up on variants of concern on a quiet day. A recent comment on this forum about reliable sources has resulted in my more selective choice ofreading material.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1109820/Technical-Briefing-46.pdf

Ultimately, I view Synairgen’s short term potential as a treatment to supplement the World wide vaccination programme. Surely BP will have identified the potential benefits of SNG001 by now? I shan’t be contacting my local MP about this. He is as powerless as I am in influencing Government strategy, which is mostly targeted on a vaccine programme, and a basic SOC treatment for hospitalised patients. SNG001 might still have a role to play depending on how Covid-19 continues to evolve?

The most important step is in getting the product on a trial. A Strive trial would be a major coup for the company but there are other ways forward as our promising recent data has identified?

Ignore the negative dissembling, and the over -positive forecasts. The latter led to disappointment, and I include myself amongst the over optimistic investors during the early part of this year. DYOR etc. There are good reasons for remaining invested as Synairgen’s strategy continues to unfold.

GLA.

Following on from yesterday’s conversation, which I briefly joined while comfortably seated at an airport, I found this recent publication to update myself on developments on the UK vaccine front. Apologies if already shared.
https://www.bmj.com/content/378/bmj-2022-070344